This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Immune-Cell Profiling Identifies a Defective Macrophage-Maresin 1 Resolution Axis as a Pathogenic Driver and Therapeutic Target in Vitiligo and Canities.
Journal of cutaneous medicine and surgery · 2026
Tyrosine phosphorylation of SHIP promotes its proteasomal degradation.
Experimental hematology · 2010
Latest funding
- $1,120,726
Targeting metabolic dysfunction to prevent the development of type 2 diabetes in people with Crohn's disease
CIHR · 2026 · Nominated PI
- $20,000
Precision nutrition to prevent type 2 diabetes in children
CIHR · 2024 · Nominated PI
- $879,750
Bespoke plant glycoconjugates to improve Inflammatory Bowel Disease treatment through gut-microbiota-mediated drug targeting
CIHR · 2024 · Nominated PI
2 publications.
Immune-Cell Profiling Identifies a Defective Macrophage-Maresin 1 Resolution Axis as a Pathogenic Driver and Therapeutic Target in Vitiligo and Canities.
Yang Q, Zhang G, Su M, Leung G, Shi Y, Cai A, Ghoreishi M, Sly L, Dutz J, Zhou P, Zhang X, Xu J, Zhou Y
Tyrosine phosphorylation of SHIP promotes its proteasomal degradation.
Ruschmann J, Ho V, Antignano F, Kuroda E, Lam V, Ibaraki M, Snyder K, Kim C, Flavell RA, Kawakami T, Sly L, Turhan AG, Krystal G
Targeting metabolic dysfunction to prevent the development of type 2 diabetes in people with Crohn's disease
Principal investigators: Sly, Laura M
Keywords: Animal Modelling; Crohn Disease; Gur Barrier Function; Gut Microbiome; Inflammatory Bowel Disease; Intestinal Inflammation; Macrophage Immunometabolism; Metabolic Dysfunction; Metabolome; Type 2 Diabetes
Precision nutrition to prevent type 2 diabetes in children
Principal investigators: Sly, Laura M; Panagiotopoulos, Constadina; Devlin, Angela M; Lunken, Genelle R; Manges, Amee R
Keywords: Crohn'S Disease; Gut Physiology (Leaky Gut); Inflammation; Insulin Resistance; Knowledge Mobilization; Microbiome; Micronutrients; Obesity Or Overweight; Precision Nutrition; Type 2 Diabetes
Bespoke plant glycoconjugates to improve Inflammatory Bowel Disease treatment through gut-microbiota-mediated drug targeting
Principal investigators: Sly, Laura M; Brumer, Harry
Keywords: Carbohydrate Chemistry; Enzyme Release; Glycobiology; Human Gut Microbiota; Inflammatory Bowel Disease; Janus Kinase Inhibitors; Mouse Modelling; Prodrug; Steroids; Thiopurines
GlycoCaged drug delivery to improve Inflammatory Bowel Disease treatment
Principal investigators: Brumer, Harry
Keywords: Carbohydrate Chemistry; Enzyme Release; Glycobiology; Human Gut Microbiota; Inflammatory Bowel Disease; Prodrug
Exploring the potential of type-1 regulatory T cells in resolution and recovery from intestinal inflammation
Principal investigators: Steiner, Theodore S
Keywords: Chimeric Antigen Receptors; Inflammatory Bowel Disease; Tissue Organoids; Tr1 Cells
Exploring the potential of type-1 regulatory T cells in treatment and recovery from intestinal inflammation in inflammatory bowel disease
Principal investigators: Steiner, Theodore S
Keywords: Cellular Therapy; Chimeric Antigen Receptors; Inflammatory Bowel Disease; Intestinal Epithelial Cells; Organoids; Regulatory T Cells
Exploring the potential of type-1 regulatory T cells in treatment and recovery from intestinal inflammation in inflammatory bowel disease
Principal investigators: Steiner, Theodore S
Keywords: Cell Therapy; Inflammatory Bowel Disease; Mucosal Inflammation; Regulatory T Cells
Hypoxia Culture Suite
Principal investigators: Beristain, Alexander
Targeting PI3-kinase p110delta to treat Crohn's disease-associated intestinal fibrosis
Principal investigators: Sly, Laura M
Keywords: Animal Models; Crohn'S Disease; Inflammatory Bowel Disease; Intestinal Fibrosis; Intestinal Inflammation; Pi3kp110delta; Samp1/Yitfc Mice; Ship
Therapeutic interventions that alter colitogenic microbiota
Principal investigators: Gibson, Deanna L; Frohlick, Susan E; Ghosh, Sanjoy; Morck, Douglas W; Sly, Laura M; Zandberg, Wesley F
Keywords: Bio Engineered Probiotics; Colonization And Persistence; Commercialization; Drug Development; Enteric Microbes; Gut Microbiome; Inflammatory Bowel Disease; Microbiome-Based Therapeutics; Mucosal Healing; Next Generation Beneficial Microbes
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.